Subscribe to our Newsletters !!

    Genes

    Researchers develop experimental direct-acting antiviral treatment to treat COVID-19

    An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19. Conventional antivirals reduce symptoms and help people recover earlier. Examples

    New gene expression organization can help understand component behind ceaseless stem cell activity in plant

    An inter-university research group has succeeded in constructing the gene expression network behind the vascular development process in plants. They achieved this by doing bioinformatics analysis using the’VISUAL’ tissue culture stage, which generates vascular stem cells from cells. Within this network, they also found a new BES/BZR transcription factor, BEH3, which modulates vascular stem cells.

    First CRISPR-Cas9-based gene drive cuts and duplicates hereditary components in Arabidopsis plants

    University of California San Diego scientists developed the first CRISPR/Cas9 based gene drive in plants. Their goal is to breed resilient crops that can withstand drought and diseases. Although gene drive technology for insects has been created to stop the spread and transmission of vector-borne diseases like Malaria, scientists in Professor Yunde Zha’s lab along

    Scientists find how Rift Valley fever virus enters cells

    Rift Valley fever virus causes economically tragic hemorrhagic outbreaks in livestock, including cattle, goats, and sheep. The mosquito-borne infections can lead to the spread of infection to people who work with animals that are dying or dead often causing many human infections as well as many deaths. Rift Valley fever, for which there isn’t a

    Novel antibody candidate shows powerful binding to different SARS-CoV-2 variant mutations

    Twist Bioscience Corporation today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to diverse SARS-CoV-2 variant mutations, including strains with the E484K, N501Y, D614G, Y453F and K417N mutations in pseudovirus assays, indicating this therapeutic antibody may be effective in treating many strains of COVID-19. The Coronavirus Immunotherapy Consortium (CoVIC) is an academic-industry-non-profit